NO991545L - FremgangsmÕte for fremstilling av liposomer med °kt prosent av innkapslet forbindelse - Google Patents

FremgangsmÕte for fremstilling av liposomer med °kt prosent av innkapslet forbindelse

Info

Publication number
NO991545L
NO991545L NO991545A NO991545A NO991545L NO 991545 L NO991545 L NO 991545L NO 991545 A NO991545 A NO 991545A NO 991545 A NO991545 A NO 991545A NO 991545 L NO991545 L NO 991545L
Authority
NO
Norway
Prior art keywords
liposomes
percent
preparation
weight
encapsulated compound
Prior art date
Application number
NO991545A
Other languages
English (en)
Norwegian (no)
Other versions
NO991545D0 (no
Inventor
Qiang Ye
Mantripragada Bhima Sankaram
Original Assignee
Depotech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Depotech Corp filed Critical Depotech Corp
Publication of NO991545D0 publication Critical patent/NO991545D0/no
Publication of NO991545L publication Critical patent/NO991545L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/829—Liposomes, e.g. encapsulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
NO991545A 1996-10-01 1999-03-30 FremgangsmÕte for fremstilling av liposomer med °kt prosent av innkapslet forbindelse NO991545L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/723,583 US5997899A (en) 1996-10-01 1996-10-01 Method for producing liposomes with increased percent of compound encapsulated
PCT/US1997/017519 WO1998014171A1 (en) 1996-10-01 1997-09-29 Method for producing liposomes with increased percent of compound encapsulated

Publications (2)

Publication Number Publication Date
NO991545D0 NO991545D0 (no) 1999-03-30
NO991545L true NO991545L (no) 1999-05-31

Family

ID=24906863

Family Applications (1)

Application Number Title Priority Date Filing Date
NO991545A NO991545L (no) 1996-10-01 1999-03-30 FremgangsmÕte for fremstilling av liposomer med °kt prosent av innkapslet forbindelse

Country Status (9)

Country Link
US (4) US5997899A (ja)
EP (1) EP1005326B1 (ja)
JP (5) JP3473959B2 (ja)
AU (1) AU738020B2 (ja)
CA (1) CA2267416C (ja)
IL (1) IL129145A0 (ja)
NO (1) NO991545L (ja)
NZ (1) NZ334837A (ja)
WO (1) WO1998014171A1 (ja)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL135060A (en) 1997-09-18 2005-12-18 Skyepharma Inc Sustained release liposomal anesthetic compositions and methods for the preparation thereof
JP4575592B2 (ja) * 1997-11-14 2010-11-04 パシラ ファーマシューティカルズ インコーポレーテッド 多小胞リポソームの製造
US7157098B1 (en) * 1998-01-06 2007-01-02 Roman Perez-Soler Gene therapy of tumors using non-viral delivery system
AU754559B2 (en) 1998-08-12 2002-11-21 New York University Liposomal bupivacaine compositions prepared using an ammonium sulfate gradient
AU2001258106A1 (en) * 2000-05-11 2001-11-20 Celator Technologies Inc. Lipid carrier compositions for improved drug retention
WO2002090510A2 (en) * 2001-05-08 2002-11-14 Emory University Regulating immine responses using dendritic cells
US20030059375A1 (en) * 2001-08-20 2003-03-27 Transave, Inc. Method for treating lung cancers
US7125568B2 (en) * 2001-08-23 2006-10-24 Sung Michael T Lipophilic drug compositions
CN100515497C (zh) * 2001-12-19 2009-07-22 研究发展基金会 脂质体输送以维生素e为基础的化合物
US20030236301A1 (en) * 2001-12-19 2003-12-25 Bob Sanders Liposomal delivery of vitamin E based compounds
US9186322B2 (en) 2002-08-02 2015-11-17 Insmed Incorporated Platinum aggregates and process for producing the same
NZ538179A (en) * 2002-08-02 2008-09-26 Transave Inc Liposome or lipid complex with active platinum compound and process for producing the same
WO2004100927A2 (de) * 2003-05-12 2004-11-25 Novosom Ag Injizierbare depots aus liposomalen aggregaten zum wirkstoffdelivery
EP1667972B1 (en) 2003-09-10 2013-06-19 Brentwood Equities Ltd. Diastereomers of 4-aryloxy-3-hydroxypiperidines
EP1696725B8 (en) * 2003-12-23 2015-07-08 Novozymes BioAG A/S Methods and compositions providing agronomically benefical effects in legumes and non-legumes
US20070065522A1 (en) * 2004-03-18 2007-03-22 Transave, Inc. Administration of high potency platinum compound formulations by inhalation
EP1729786A4 (en) * 2004-03-18 2008-03-26 Transave Inc ADMINISTRATION OF CISPLATIN BY INHALATION
CA2821167C (en) 2004-05-03 2016-06-28 Merrimack Pharmaceuticals, Inc. Drug delivery liposomes containing anionic polyols or anionic sugars
AU2005245018A1 (en) * 2004-05-21 2005-12-01 Transave, Inc. Treatment of lung diseases and pre-lung disease conditions
KR100618033B1 (ko) 2004-06-21 2006-08-30 에이엔에이치 케어연구소(주) 염산독세핀을 유효성분으로 함유하는 아토피 질환 치료용외용제 조성물
MX2007004955A (es) * 2004-11-08 2007-06-14 Transave Inc Metodo de tratar cancer con formulaciones de compeusto de platino a base de lipido administradas intraperitonealmente.
MX2007009960A (es) 2005-02-18 2008-03-11 Abraxis Bioscience Inc Combinaciones y metodos de administracion de agentes terapeuticos y terapia de combinacion.
US20070110674A1 (en) * 2005-07-29 2007-05-17 Yuhong Xu Sono-active liposomes and lipid particles and use thereof as contrast agents and active-agent delivery systems
CN1913508B (zh) * 2005-08-08 2010-05-05 华为技术有限公司 基于正交频分复用的信号调制方法及其调制装置
WO2007056264A2 (en) * 2005-11-08 2007-05-18 Transave, Inc. Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
US9107824B2 (en) 2005-11-08 2015-08-18 Insmed Incorporated Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
JP2010501011A (ja) * 2006-08-16 2010-01-14 オースペックス・ファーマシューティカルズ・インコーポレイテッド オピオイド鎮痛薬の調製および効用
EP2502617B1 (en) 2009-11-20 2019-03-20 Konica Minolta Holdings, Inc. Process for production of w/o/w emulsion, process for production of liposome employing the process, and porous membrane for use in the methods
US9770414B2 (en) 2010-05-13 2017-09-26 Pacira Pharmaceuticals, Inc. Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent
ES2634669T3 (es) 2011-02-08 2017-09-28 Halozyme, Inc. Composición y formulación lipídica de una enzima de degradación de hialuronano y uso de la misma para el tratamiento de la hiperplasia benigna de próstata
US9668974B2 (en) 2012-05-10 2017-06-06 Painreform Ltd. Depot formulations of a local anesthetic and methods for preparation thereof
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
ES2848025T3 (es) 2012-09-04 2021-08-05 Eleison Pharmaceuticals LLC Prevención de la recidiva pulmonar del cáncer con cisplatino complejado con lípidos
BR112015022171B1 (pt) 2013-03-14 2023-01-03 Fresenius Kabi Deutschland Gmbh Sistema de embalagem farmacêutica para um fármaco sensível ao oxigênio injetável
CA2902343C (en) 2013-03-14 2022-08-02 Becton Dickinson France S.A.S. Injectable morphine formulations
US9956195B2 (en) 2014-01-07 2018-05-01 Nanyang Technological University Stable liposomal formulations for ocular drug delivery
WO2016033555A1 (en) 2014-08-28 2016-03-03 Halozyme, Inc. Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor
JP2018502870A (ja) * 2015-01-21 2018-02-01 パシラ ファーマシューティカルズ インコーポレーテッド トラネキサム酸の多小胞リポソーム処方物
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
TWI724018B (zh) 2015-08-20 2021-04-11 英商益普生生物製藥有限公司 用於癌症治療之組合療法
EP3337478B1 (en) 2015-08-21 2020-08-12 Ipsen Biopharm Ltd. Drug combination comprising liposomal irinotecan, oxaliplatin, 5-fluorouracil and leucovorin for treating metastatic pancreatic cancer
SG10201912568PA (en) 2015-10-16 2020-02-27 Ipsen Biopharm Ltd Stabilizing camptothecin pharmaceutical compositions
MX2019004783A (es) 2016-11-02 2019-08-12 Ipsen Biopharm Ltd Tratamiento de cancer gastrico usando terapias de combinacion que comprenden irinotecan liposomico oxaliplatino, 5-fluoruracilo (y leucovorina).
US11684579B2 (en) 2018-04-27 2023-06-27 Karma Biotechnologies Multi-vesicular liposomes for targeted delivery of drugs and biologics for tissue engineering
US11033495B1 (en) 2021-01-22 2021-06-15 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11357727B1 (en) 2021-01-22 2022-06-14 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11278494B1 (en) 2021-01-22 2022-03-22 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH588887A5 (ja) * 1974-07-19 1977-06-15 Battelle Memorial Institute
US4897308A (en) * 1975-06-30 1990-01-30 L'oreal Compositions comprising aqueous dispersions of lipid spheres
US4078052A (en) * 1976-06-30 1978-03-07 The United States Of America As Represented By The Secretary Of Health, Education And Welfare Large unilamellar vesicles (LUV) and method of preparing same
US4086257A (en) * 1976-10-12 1978-04-25 Sears Barry D Phosphatidyl quaternary ammonium compounds
CH624011A5 (ja) * 1977-08-05 1981-07-15 Battelle Memorial Institute
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4310506A (en) * 1979-02-22 1982-01-12 California Institute Of Technology Means of preparation and applications of liposomes containing high concentrations of entrapped ionic species
JPS55153713A (en) * 1979-05-02 1980-11-29 Kureha Chem Ind Co Ltd Pharmaceutical preparation of ribosome containing active substance
US4394372A (en) * 1980-12-22 1983-07-19 The Procter & Gamble Company Process for making lipid membrane structures
US4522803A (en) * 1983-02-04 1985-06-11 The Liposome Company, Inc. Stable plurilamellar vesicles, their preparation and use
US4588578A (en) * 1983-08-08 1986-05-13 The Liposome Company, Inc. Lipid vesicles prepared in a monophase
US4599227A (en) * 1983-11-07 1986-07-08 Wisconsin Alumni Research Foundation Injectable pharmaceutical preparation for the induction of multiple follicular growth
US4610868A (en) * 1984-03-20 1986-09-09 The Liposome Company, Inc. Lipid matrix carriers for use in drug delivery systems
US5077056A (en) * 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
IE58981B1 (en) * 1985-10-15 1993-12-15 Vestar Inc Anthracycline antineoplastic agents encapsulated in phospholipid micellular particles
US5204112A (en) * 1986-06-16 1993-04-20 The Liposome Company, Inc. Induction of asymmetry in vesicles
US4877619A (en) * 1986-08-25 1989-10-31 Vestar, Inc. Liposomal vesicles for intraperitoneal administration of therapeutic agents
US4752425A (en) * 1986-09-18 1988-06-21 Liposome Technology, Inc. High-encapsulation liposome processing method
US4781871A (en) * 1986-09-18 1988-11-01 Liposome Technology, Inc. High-concentration liposome processing method
US4920016A (en) * 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
US5723147A (en) * 1987-02-23 1998-03-03 Depotech Corporation Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride
JP2666345B2 (ja) * 1987-04-16 1997-10-22 武田薬品工業株式会社 リポソーム製剤およびその製造法
US4921644A (en) * 1988-02-29 1990-05-01 Technology Unlimited, Inc. Mucin directed lipsome
US5422120A (en) * 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
BE1001869A3 (fr) * 1988-10-12 1990-04-03 Franz Legros Procede d'encapsulation liposomiale d'antibiotiques aminoglucosidiques, en particulier de la gentamycine.
DE69331330T2 (de) * 1992-10-14 2002-07-11 Liposome Co Inc Interdigitation-fusionsliposomen und gels
AU6832794A (en) * 1993-05-19 1994-12-12 Liposome Company, Inc., The Liposome having a multicomponent bilayer which contains a bioactive agent as an integral component of the bilayer
US5766627A (en) 1993-11-16 1998-06-16 Depotech Multivescular liposomes with controlled release of encapsulated biologically active substances
US5993850A (en) * 1994-09-13 1999-11-30 Skyepharma Inc. Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances

Also Published As

Publication number Publication date
JP3473959B2 (ja) 2003-12-08
AU738020B2 (en) 2001-09-06
US6241999B1 (en) 2001-06-05
EP1005326A4 (en) 2006-03-22
JP2003327526A (ja) 2003-11-19
CA2267416C (en) 2007-03-27
IL129145A0 (en) 2000-02-17
JP2001505549A (ja) 2001-04-24
WO1998014171A1 (en) 1998-04-09
EP1005326B1 (en) 2017-05-17
NO991545D0 (no) 1999-03-30
JP2003327525A (ja) 2003-11-19
EP1005326A1 (en) 2000-06-07
CA2267416A1 (en) 1998-04-09
US6193998B1 (en) 2001-02-27
JP2003327544A (ja) 2003-11-19
JP2008163040A (ja) 2008-07-17
AU4657997A (en) 1998-04-24
NZ334837A (en) 2000-09-29
US5997899A (en) 1999-12-07
US6171613B1 (en) 2001-01-09

Similar Documents

Publication Publication Date Title
NO991545L (no) FremgangsmÕte for fremstilling av liposomer med °kt prosent av innkapslet forbindelse
NO975775L (no) Fremgangsmåte for fremstilling av forbindelser med antifungal aktivitet
NO20011936L (no) Fremgangsmate for fremstilling av citalopram
NO177525C (no) FremgangsmÕte for fremstilling av et kombinert anti- inflammatorisk preparat
NO20015017D0 (no) Fremgangsmåte for fremstilling av citalopram
FI20010155A (fi) Menetelmä citalopramin valmistamiseksi
NO20010318D0 (no) Fremgangsmåte for fremstilling av Citalopram
NO931972D0 (no) Preparat for fjerning av maling
FI103666B (fi) Menetelmä bifenyylijohdannaisen valmistamiseksi
NO20004288D0 (no) FremgangsmÕte til fremstilling av et beskyttet 4-aminometyl- pyrrolidin-3-on
NO963217L (no) Fremgangsmåte for fremstilling av et salt av clavulansyre
NO20062796L (no) Fremgangsmate for fremstilling av en dihydroksyaminoforbindelse
NO952423D0 (no) Ekspresjonsvektorer for produksjon av transgen fisk
NO974155D0 (no) Ny fremgangsmåte for fremstilling av 2,3-dihydrobenzofuranolderivater
GB9414440D0 (en) Improvements to the protection of plants
NO924891D0 (no) Fremgangsmaate for fremstilling av et frittstroemmende, pulverformig, toeymyknende preparat
NO180675C (no) Fremgangsmåte for fremstilling av aromatiske forbindelser
NO931839L (no) Fremgangsm}te for fremstilling av pergolid
NO985859D0 (no) FremgangsmÕte for fremstilling av Õpningsmidler for en forpakning
FI971964A0 (fi) Menetelmä 1-halo-3-trialkyylisilasnyylibentseenijohdannaisten valmistamiseksi
FI961717A (fi) Menetelmä oraalisten, kinoloneja sisältävien valmisteiden valmistamiseksi
DE69502982T2 (de) Herstellung geschützter Aminothiazolylessigsäurederivate
GB9415312D0 (en) The preparation of organic compounds
FI951441A0 (fi) Menetelmä 5-formyyliamino-pyrimidiinien valmistamiseksi
ZA956176B (en) The preparation of organic compounds